Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury

Dipyridamole Acts as Clinical Ferroptosis Inhibitor to Prevent from Tissue Injury

Abstract Ferroptosis is a newly identified cell death triggered by iron‐induced lipid peroxidation. Numerous studies reveal that ferroptosis participates in multiple types of tissue injury including ischaemia–reperfusion (I/R) injury and doxorubicin (Dox)‐induced damage. Targeting ferroptosis is a p...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiao Zhuang, Shuang Shi, Shuo Liu, Yaqiong Jiao, Bin Huang, Yinghong Yang, Li Yang, Xinquan Yang, Hui Wang, Chunhui Liang, Dandan Song, Huaxiang Yu, Dan Zou, Qi Sun, Shu Yang, Chengqian Yin, Jian Li, Yiming Liu, Junxia Min, Fudi Wang, Yong Nian, Lutao Du, Bo Chu
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Advanced Science
Subjects:
dipyridamole
ferroptosis
SLC7A11
tissue injury
Online Access:https://doi.org/10.1002/advs.202500566
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Ferroptosis is a newly identified cell death triggered by iron‐induced lipid peroxidation. Numerous studies reveal that ferroptosis participates in multiple types of tissue injury including ischaemia–reperfusion (I/R) injury and doxorubicin (Dox)‐induced damage. Targeting ferroptosis is a promising approach for disease treatment as the blockade of ferroptosis efficiently alleviates the symptoms. However, no known ferroptosis inhibitors have been used for clinical treatment. Although certain clinical compounds act as ferroptosis inhibitors in vitro, whether these drugs cure tissue injury by suppressing ferroptosis is little known. Here, by screening a large panel of drugs used in the clinic, it is identified that dipyridamole significantly attenuates Dox or I/R‐induced cardiac injury. Moreover, dipyridamole can achieve a good therapeutic effect on  liver and kidney injury. Mechanistically, dipyridamole‐mediated ferroptosis inhibition is strictly dependent on solute carrier family 7 member 11 (SLC7A11). Dipyridamole down‐regulates the expression of ring finger protein 126 (RNF126), which is an E3 ligase to ubiquitinate SLC7A11 for proteasome degradation. Deficiency of SLC7A11 largely blocks the protective role of dipyridamole in vitro and in vivo. Together, the findings uncover that dipyridamole acts as a clinical compound to alleviate organ injury via suppressing ferroptosis, providing novel insights into the clinical therapy for ferroptosis‐related tissue damage.
ISSN:2198-3844

Similar Items